Immune Globulin Articles
Sharp rise in US FDA approvals of biopharmaceuticals in 2009, highest since 2005, says BII
18 January 2010
Octapharma submits BLA to US FDA for octagam 10%
24 September 2009
Talecris Gamunex beats placebo in CIDP trial
27 April 2009
Baxter presents data validating Gammagard
23 March 2009
Halozyme gets $5.5M Baxter payment
12 January 2009
Talecris buy could see CSL become leader in IVIG sales, says AMR
24 November 2008
Baxter sales up 15% in 3rd-qtr 2008
27 October 2008
Grifols breaks ground on new IVIG facility
13 October 2008
Baxter initiates Ph III AD trial for Gammagard
29 September 2008
FDA approves Talecris' orphan drug for CIDP
22 September 2008
Possible role for Gammagard in AD
28 April 2008
CSL Behring enters deal for Canada
14 April 2008
Cangene gets orphan status for HepaGam
7 April 2008
Talecris' Gamunex cuts disability in CIDP
18 February 2008
Germany's Biotest buys Nabi unit for $185M
17 September 2007
FDA clears Cangene's HepaGam B for HBV
16 April 2007
Australia's CSL to up R&D expenditure
2 April 2007
Baxter's 4th-qtr net earnings up 47%
5 February 2007
ZLB buys MedImmune's CytoGam for $50M
22 December 2006
MedImmune sells CytoGam to ZLB Behring
13 November 2006
US govt buys anthrax drug from Cangene
7 August 2006
ZLB Behring's Vivaglobin approved in UK
1 May 2006
FDA approves ZLB Behring's Vivaglobin for PIDD
16 January 2006
New year brings new Medicare regime
9 January 2006
Baxter's IVIg receives European approval
5 December 2005
Inhibitex raises $41M in private financing
22 August 2005
Nabi's Civacir receives orphan status from EC
4 July 2005
Crucell evaluating MAb against rabies
22 November 2004
Inhibitex announces $50M financing
15 November 2004
Nabi's 3rd-qtr 2004 profit takes a dive
25 October 2004
DVC's BLA for vaccinia immune globulin accepted by FDA
9 August 2004
MedImmune's 2nd-qtr plunges into loss
2 August 2004
Bayer Biologicals moves to stop counterfeiting
26 July 2004
FDA OKs Octapharma's IGIV product
31 May 2004
Nabi's Altastaph on FDA fast-track
15 March 2004
Acambis reviews strategic projects
9 February 2004
Spain's Probitas gets FDA approval for its IVIG Flebogamma
19 January 2004
FDA responds to Nabi's BLA for Nabi-HB
16 June 2003
Acambis deal for Cangene's vaccinia immune globulin
17 March 2003
Bayer retains Canadian blood products supply deal
6 January 2003
Baxter starts Ph III trial of new immune globulin
22 July 2002
Busy year for NCEs as major new compound classes launched
6 January 2000
HMO "not dropping Prozac or Prilosec"
21 April 1999
US approval for Nabi's HBV immune globulin
31 March 1999
Nabi Files IND In USA For Hep B Drug
14 December 1998
Nabi Files IND with FDA For Reformulated Hepatitis B Immune Globulin
19 November 1998
Nabi's H-BIG Gets Priority Review Status From FDA
22 September 1998
Nabi Submit PLA For H-BIG
20 August 1998
FDA Clears MedImmune's Synagis For RSV
22 June 1998
Immune Globulin Shortage: Are Companies Hoarding?
30 April 1998
Clinical Trial News In Brief
22 January 1998
MedImmune Granted Canadian Approval For RespiGam
28 August 1997
MedImmune's CytoGam Cleared In Canada
7 August 1997
US Biopharma Firms See Research Bear Fruit In '96
17 February 1997
Biopharmaceutical Firms Report On 2nd Qtr
12 August 1996
Second Application For RespiGam
8 July 1996
Neozyme II And Nabi To Cease HyperGam+ Trial
1 July 1996
Important Developments For US Biotechnology Cos
19 February 1996
RespiGam Licensed In First Market
29 January 1996
Baxter's Gammagard linked to hepatitis
31 July 1995
PREVENT Trial Results Presented
24 July 1995
Univax Biologics Focusing On Core Activities
22 May 1995
US FDA Approves Univax' WinRho
3 April 1995
SB's Havrix Approved In The USA
27 February 1995
Highlights Of SmithKline's R&D Portfolio
2 January 1995
GAMMAGARD ADVERSE REACTIONS
1 August 1994
SAFER GAMMAGARD APPROVED IN USA
23 May 1994
BAXTER WITHDRAWS GAMMAGARD
14 March 1994
BAD NEW FOR MEDIMMUNE AS RESPIGAM STUMBLES
13 December 1993
NIH/NORTH AMERICAN BIOLOGICALS COOPERATION
19 July 1993
MILES' GAMIMUNE in PEDIATRIC HIV
24 May 1993
CYMEVENE AND HEART TRANSPLANTS
11 May 1992
Showing 1-82 of 82 articles
- 1
- US Supreme Court says patent settlement can "sometimes" be illegal
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Daiichi Sankyo files for Japanese approval of Prasugrel
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
